Deep knowledge on 
 small-molecule drugs and 
 the 110,000 global patents 
 covering them 

Free Patent Expiration Alerts


Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Rizatriptan benzoate - Generic Drug Details

« Back to Dashboard
Rizatriptan benzoate is the generic ingredient in three branded drugs marketed by Glenmark Generics, Cipla Ltd, Sandoz, Jubilant Generics, Invagen Pharms, Apotex Inc, Macleods Pharms Ltd, Nostrum Labs Inc, Aurobindo Pharma Ltd, Teva Pharms, Merck, Alkem Labs Ltd, Mylan Pharms Inc, Natco Pharma Ltd, and Emcure Pharms Ltd, and is included in twenty-four NDAs. Additional information is available in the individual branded drug profile pages.

There are twenty-two drug master file entries for rizatriptan benzoate. Twenty-seven suppliers are listed for this compound.

Summary for Generic Name: rizatriptan benzoate

Tradenames:3
Patents:0
Applicants:15
NDAs:24
Drug Master File Entries: see list22
Suppliers / Packaging: see list27
Therapeutic Class:Antimigraine Agents

Pharmacology for Ingredient: rizatriptan benzoate

Clinical Trials for: rizatriptan benzoate

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Macleods Pharms Ltd
RIZATRIPTAN BENZOATE
rizatriptan benzoate
TABLET;ORAL203147-002Feb 11, 2014RXNo<disabled><disabled>
Glenmark Generics
RIZATRIPTAN BENZOATE
rizatriptan benzoate
TABLET, ORALLY DISINTEGRATING;ORAL201914-002Jul 1, 2013RXNo<disabled><disabled>
Alkem Labs Ltd
RIZATRIPTAN BENZOATE
rizatriptan benzoate
TABLET;ORAL203269-002Feb 18, 2016RXNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: rizatriptan benzoate

These historical archives are available as an add-on to one-year subscriptions.
See the Signup Form for more information.

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck
MAXALT-MLT
rizatriptan benzoate
TABLET, ORALLY DISINTEGRATING;ORAL020865-002Jun 29, 19984,371,516<disabled>
Merck
MAXALT-MLT
rizatriptan benzoate
TABLET, ORALLY DISINTEGRATING;ORAL020865-001Jun 29, 19984,305,502<disabled>
Merck
MAXALT-MLT
rizatriptan benzoate
TABLET, ORALLY DISINTEGRATING;ORAL020865-001Jun 29, 19984,371,516<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Connect with Social Media:

`abc